{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:38Z","timestamp":1783696658888,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.radonc.2019.02.018","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T17:08:14Z","timestamp":1551805694000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-4560","authenticated-orcid":false,"given":"David","family":"B\u00fcchser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Casquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Minguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorea","family":"Martinez-Indart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernan","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Cacicedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Maleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gomez-Caama\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Gomez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2019.02.018_b0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0010","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase iii trial comparing 68 Gy of radiotherapy With 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with Gleason score 9\u201310 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis","author":"Kishan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2019.02.018_b0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clon.2013.01.001","article-title":"Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.brachy.2016.04.002","article-title":"Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: with or without supplemental external beam radiotherapy","volume":"15","author":"Serrano","year":"2016","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2016.02.004","article-title":"Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial","volume":"119","author":"Gomez-Iturriaga","year":"2016","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0050","article-title":"Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy","volume":"8","author":"Buchser","year":"2016","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2019.02.018_b0055","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0060","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0065","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0070","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2017.12.025","article-title":"Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer","volume":"127","author":"\u00c5str\u00f6m","year":"2018","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.radonc.2018.04.031","article-title":"Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer","volume":"128","author":"Strouthos","year":"2018","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clon.2017.01.042","article-title":"Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer","volume":"29","author":"Shahid","year":"2017","journal-title":"Clin Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.brachy.2017.01.006","article-title":"Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: an Asian Prostate HDR-BT Consortium","volume":"16","author":"Ishiyama","year":"2017","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0100","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1080\/0284186X.2017.1349333","article-title":"Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy","volume":"56","author":"Lakosi","year":"2017","journal-title":"Acta Oncol (Madr) [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brachy.2015.12.008","article-title":"Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: comparison of two consecutive high-dose-rate schemes","volume":"15","author":"Olarte","year":"2016","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brachy.2014.11.005","article-title":"Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects","volume":"14","author":"Kishan","year":"2015","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2015.08.019","article-title":"Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy","volume":"117","author":"Sutani","year":"2015","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.13659","article-title":"Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years","volume":"120","author":"Yaxley","year":"2017","journal-title":"BJU Int [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0125","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.brachy.2015.04.004","article-title":"High-dose-rate brachytherapy boost for prostate cancer: outcomes and genitourinary toxicity","volume":"14","author":"Bece","year":"2015","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0130","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.brachy.2017.03.002","article-title":"High-dose-rate brachytherapy boost for prostate cancer: analysis of dose-volume histogram parameters for predicting late rectal toxicity","volume":"16","author":"Chicas-Sett","year":"2017","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.brachy.2017.06.013","article-title":"High-dose-rate brachytherapy boost for prostate cancer: comparison of three different fractionation schemes","volume":"16","author":"Falk","year":"2017","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.brachy.2016.10.008","article-title":"Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer","volume":"16","author":"Kragelj","year":"2017","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5114\/jcb.2016.59216","article-title":"Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results","volume":"2","author":"Lauche","year":"2016","journal-title":"J Contemp Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jrr\/rrw003","article-title":"Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes","volume":"57","author":"Liu","year":"2016","journal-title":"J Radiat Res [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0155","article-title":"Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: a single institution experience","author":"Ng","year":"2017","journal-title":"Asia Pac J Clin Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2017.12.025","article-title":"Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer","volume":"127","author":"\u00c5str\u00f6m","year":"2018","journal-title":"Radiother Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.brachy.2017.04.242","article-title":"Clinical factors and dosimetry associated with the development of prostate brachytherapy-related urethral strictures: a matched case-control study","volume":"16","author":"Singhal","year":"2017","journal-title":"Brachytherapy [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0170","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ijrobp.2010.01.069","article-title":"Rectal toxicity on RTOG 94\u201306: analysis using a mixture lyman model","volume":"78","author":"Tucker","year":"2010","journal-title":"Int J Radiat Oncol [Internet]"},{"key":"10.1016\/j.radonc.2019.02.018_b0175","doi-asserted-by":"crossref","first-page":"17383","DOI":"10.18632\/oncotarget.14798","article-title":"Rectal\/urinary toxicity after hypofractionated vs conventional radiotherapy in low\/intermediate risk localized prostate cancer: systematic review and meta analysis","volume":"8","author":"Di Franco","year":"2017","journal-title":"Oncotarget [Internet]"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814019301008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814019301008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:06:38Z","timestamp":1759122398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814019301008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":35,"alternative-id":["S0167814019301008"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2019.02.018","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2019.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}